Practitioner Perspective: Pressure points on pharmaceutical industry executives: What lies ahead?

International Journal of Pharmaceutical and Healthcare Marketing

Volumn 3, Issue 1, 2009, Pages 74-83

  Glass, Harold E ^a,b   Poli, Laurence G ^c  

^a UNIVERSITY OF THE SCIENCES   (United States)

^b TTC   (United States)

^c Center for Performance Excellence   (United States)

Author keywords

Drugs; Pharmaceuticals industry; Research and development

Indexed keywords

EID: 70149091223     PISSN: 17506123     EISSN: None     Source Type: Journal    
DOI: 10.1108/17506120910948520     Document Type: Article

References (26)

1. Anderson, G., Juurlink, D. and Detsky, A.S. (2008), Newly approved does not always mean new and improved, The Journal of the American Medical Association, Vol. 299 No. 13, p. 1598.
2. Catlin, A., Cowan, C., Hartman, M. and Heffler, S. (2008), National health spending in 2006: a year of change for prescription drugs, Health Spending, Vol. 21 No. 1, pp. 14-29.
3. Dickinson, J. (2007), As I see it, Medical Marketing and Media, Vol. 42 No. 4, p. 14.
4. DiMasi, J.A. and Grabowski, H.G. (2007), The cost of biopharmaceutical R&D: is biotech different?, Managerial and Decision Economics, Vol. 28 Nos 4/5, pp. 469-79.
5. DiMasi, J.A., Hansen, R.W. and Grabowski, H.G. (2003), The price of innovation: new estimates of drug development costs, Journal of Health Economics, Vol. 22 No. 2, pp. 151-85.
6. Duffield, C. (1988), The Delphi technique, Australian Journal of Advanced Nursing, Vol. 6, pp. 41-5.
7. Fabrigar, L.R., Wegener, D.T., MacCallum, R.C. and Strahan, E.J. (1999), Evaluating the use of exploratory factor analysis in psychological research, Psychological Methods, Vol. 4, pp. 272-99.
8. Jarvis, L.M. (2007a), Pharma's tough balancing act, Chemical & Engineering News, Vol. 85 No. 47, p. 32.
9. Jarvis, L.M. (2007b), Biotech challenges, Chemical & Engineering News, Vol. 85 No. 47, p. 34.
10. Keyhani, S. (2008), FDA drug review deadlines: a safety concern?, Journal of Clinical Outcomes Management, Vol. 15 No. 5, p. 224.
11. Klein, L. (2008), Navigating restricted waters, Medical Marketing and Media, Vol. 43 No. 4, pp. 49-53.
12. Leiden, J.M. (2008), Canaries, coal mines and the drug supply, Nature Biotechnology, Vol. 26 No. 6, pp. 624-6.
13. Lopert, R. and Moon, M. (2007), Toward a rational, value-based drug benefit for medicare, Health Affairs, Vol. 26 No. 6, pp. 1666-73.
14. Olson, M.K. (2002), Pharmaceutical policy change and the safety of new drugs, Journal of Law & Economics, Vol. 45 No. 2, pp. 615-42.
15. Ozdemir, V. and Williams-Jones, B. (2006), Democracy unleashed - unpacking the tooth fairy in drug industry R&D, Nature Biotechnology, Vol. 24 No. 11, p. 1324.
16. Patterson, J. (2008), Can big Pharma produce the next generation of medicines?, Pharmaceutical Technology, Vol. 32 No. 8, pp. 114-5.
17. Rajamki, H. (2008), Anticipating and managing the challenges of biotechnology marketing, Journal of Commercial Biotechnology, Vol. 14 No. 3, pp. 225-31.
18. Steinbrook, R. (2007), Election 2008 - Campaign contributions, lobbying, and the US health sector, The New England Journal of Medicine, Vol. 357 No. 8, p. 736.
19. Truelove, C. (2006), Necessary steps, Med Ad News, Vol. 25 No. 1, p. 18.
20. US Government Accountability Office (2006), New Drug Development: Science, Business, Regulatory and Intellectual Property Issues Cited as Hampering Drug Development Efforts, GAO-07-49, Government Accountability Office, Washington, DC.
21. Yager, J.A. and Starrett, R. (2006), Issues facing development of new innovative medicines, Drug Information Journal, Vol. 40 No. 3, pp. 281-90.
22. Zhong, X. and Moseley, G.B. (2007), Mission possible: managing innovation in drug discovery, Nature Biotechnology, Vol. 25 No. 8, pp. 945-6.
23. Chase, J. (2008), Good people, good business, Medical Marketing and Media, Vol. 43 No. 5, p. 6.
24. Lewis, D., Bramley-Harker, E. and Farahnik, J. (2007), Economic drivers of pharmaceutical investment location/response, World Economics, Vol. 8 No. 3, p. 171.
25. Tucker, J., Yakatan, S. and Yakatan, S. (2008), Biogenerics 2007: how far have we come?, Journal of Commercial Biotechnology, Vol. 14 No. 1, pp. 56-64.
26. Vinten, G. (2007), Excessive medical spending: facing the challenge, The Journal of the Royal Society for the Promotion of Health, Vol. 127 No. 6, p. 288.